HKBU has developed a technology relates to the identification and therapeutic potential of oleanolic acid and plant extracts, particularly Chaenomelis Fructus, for treating glucose-6-phosphate dehydrogenase (G6PD) deregulated disorders, including Bag3opathy, amyotrophic lateral sclerosis (ALS), Huntington disease, Parkinson disease, and Alzheimer disease.
This invention addresses the issue for lack of effective treatments for glucose-6-phosphate dehydrogenase (G6PD)-deregulated disorders, including BAG3opathy and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Huntington disease, Parkinson disease, and Alzheimer disease.
Aspiring to be a leading, research-led, liberal arts University in Asia, Hong Kong Baptist University is committed to conducting world-leading investigations that extends the frontiers of knowledge, tackles global challenges and benefits the community at home and abroad.
Pursuing research excellence is one of the priorities of the University’s Institutional Strategic Plan 2018-2028. The University keeps enhancing its capacity and strength to produce world-class research with an aim to bring significant impact to the society.